Smooth sailing for NeuroDiscovery

By Staff Writers
Tuesday, 22 July, 2008

Perth biotech NeuroDiscovery has successfully completed an early stage trial of its neuropathic pain candidate NSL-043.

The compound, previously developed by another company for inflammatory disease, was successful in single ascending dose clinical trials and has now completed a multiple ascending dose trail.

The company said the compound's adverse event profile demonstrated good safety and tolerability.

NeuroDiscovery is also investigating the development of antagonists of the connexin and pannexin families of gap junction proteins.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd